Answer
Bruising was reported in 33.3% of patients taking Jakavi (ruxolitinib phosphate) for myelofibrosis and was among the three most frequent non-haematological adverse drug reactions.
Sources for this answer
- Jakavi 5mg, 10mg, 15mg and 20mg TabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 29Document updated
Sources checked